摘要:
A compound of formula (I): ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a bond or oxygen; Y is --(CH.sub.2).sub.n -- where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen; may be used in the prophylaxis and treatment of diseases whose symptoms are controlled by the mediators of the allergic response, for example asthma, hay-fever, rhinitis and allergic eczema.
摘要:
Bicyclic compounds useful in the prophylaxis and treatment of allergic diseases, pharmaceutical compositions containing the same, methods of administration of the compositions, intermediates useful in preparing the compounds and conversion of the intermediates to the bicyclic compounds. Examples of compounds are substituted coumarins and indanediones and their pharmaceutically acceptable salts.
摘要:
A method for synthesizing (RS)-Warfarin comprising preparing a liquid mixture, wherein the liquid mixture comprises trihexyltetradecylphosphonium bromide, methyl salicylate, acetyl chloride, benzaldehyde, and acetone. The method may further comprise incubating the liquid mixture at a temperature between 20° C. and 30° C. for a time duration between 26 and 34 minutes, and forming (RS)-Warfarin by adding water to the incubated liquid mixture with a volume ratio (water:incubated liquid mixture) between 1:1 and 1.5:1.
摘要:
A method for synthesizing (RS)-Warfarin comprising preparing a liquid mixture, wherein the liquid mixture comprises trihexyltetradecylphosphonium bromide, methyl salicylate, acetyl chloride, benzaldehyde, and acetone. The method may further comprise incubating the liquid mixture at a temperature between 20° C. and 30° C. for a time duration between 26 and 34 minutes, and forming (RS)-Warfarin by adding water to the incubated liquid mixture with a volume ratio (water:incubated liquid mixture) between 1:1 and 1.5:1.
摘要:
Disclosed is a configurational stereoisomer, named enantiomer E1, of flocoumafen, the enantiomer E1 having, by chromatographic analysis of flocoumafen performed under particular conditions, a retention time t1 having a value such that t1
摘要:
Disclosed is a configurational stereoisomer, named enantiomer E3, of flocoumafen, the enantiomer E3 having, by chromatographic analysis of flocoumafen performed under particular conditions, a retention time t3 having a value such that t1
摘要:
Provided herein are methods for the biosynthesis of 4-hydroxycoumarin. In one embodiment, provided herein are genetically engineered microbes that include a metabolic pathway for the production of 4-hydroxycoumarin. Also provided are methods for using the genetically engineered microbes to produce 4-hydroxycoumarin, and using the 4-hydroxycoumarin as the starting point for the synthesis of other compounds.
摘要:
Compounds including those of the Formula I where X, R1, R2 and subscript t are as defined herein, useful as γ-secretase inhibitors, are provided, as are compositions comprising the compounds, as well as methods for use of the compounds for treating or preventing neurodegenerative diseases, such as, for instance, Alzheimer's disease.
摘要:
Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer.